Based on its evaluation of the August 2021 Indemnity Agreement, the Company has determined that it is highly unlikely that the events covered under the August 2021 Indemnity Agreement would occur, and consequently, the Company has not recorded any indemnification liability associated with the August 2021 Indemnity Agreement.
On January 24, 2022, the Company entered into a receivable purchase agreement (the “January 2022 Receivable Purchase Agreement”) with Purchaser.
Pursuant to the terms and conditions set forth in the January 2022 Receivable Purchase Agreement, the Company sold $400,680, a portion of its calendar 2021 CMS receivable, for $387,035, of which $359,388 was received on January 24, 2022. The remaining $27,647, which is included in accounts receivable, net as of February 26, 2022, is payable to the Company, subject to final CMS claim reconciliation adjustments, upon receipt of the final remittance from CMS. In connection therewith, the Company recognized a loss of $13,645, which is included as a component of loss (gain) on sale of assets, net during the thirteen week period ended February 26, 2022.
On January 24, 2022, concurrent with the January 2022 Receivable Purchase Agreement, the Company entered into an indemnity agreement (the “January 2022 Indemnity Agreement”), whereby the Company has agreed to indemnify, reimburse and hold Purchaser harmless from certain liabilities and expenses actually suffered or incurred by the Purchaser resulting from the occurrence of certain events as specified in the January 2022 Indemnity Agreement. Based on its evaluation of the January 2022 Indemnity Agreement, the Company has determined that it is highly unlikely that the events covered under the January 2022 Indemnity Agreement would occur, and consequently, the Company has not recorded any indemnification liability associated with the January 2022 Indemnity Agreement.
During the thirteen week period ended November 27, 2021, the Company incurred additional fees of $2,049, which are included as a component of gain on sale of asset, net, related to the sale of the 2020 CMS Receivable to Bank of America. The additional fees were incurred due to a CMS delay in settling the 2020 CMS receivable. On January 3, 2022, the final remittance of the calendar 2020 CMS receivable was received and, pursuant to their terms and conditions, used to settle the November 2020 and February 2021 Receivable Purchase Agreements with Bank of America.
As of February 26, 2022 and February 27, 2021 accounts receivable, net included $34,898 and $52,718 due from the Purchaser, subject to final CMS claim reconciliation adjustments, upon receipt of the final remittance for the respective calendar years from CMS.
As of February 26, 2022, accounts receivable, net included $63,203 of amounts due from CMS. As of February 27, 2021, accounts receivable, net included $69,800 of amounts due from CMS.
11. Manufacturer Rebates Receivables
The Pharmacy Services Segment has manufacturer rebates receivables of $535,620 and $632,267 included in Accounts receivable, net of an allowance for uncollectible rebates of $18,796 and $10,132, as of February 26, 2022 and February 27, 2021, respectively.
During the thirteen week period ended February 26, 2022, the Company reassessed its historical policy for estimating its allowance for manufacturer rebate receivables and concluded that, due to changes in its business practices and other market conditions, certain amounts within the outstanding receivable had an increased risk of uncollectability. As a result, the Company increased its allowance for manufacturer rebate receivables by $15,068, which was recorded as